SCHEMBL6316062

SCHEMBL6316062

NC(=O)c1c(-c2ccsc2)noc1NC(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.41
STAT3 P40763 1/20 0.41
STAT1 P42224 1/20 0.41
PTGS1 P23219 5/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PTGER4 P35408 1/20 0.39
P2RY14 Q15391 2/20 0.39
DEGS1 O15121 1/20 0.39
PDGFRB P09619 1/20 0.38
KDR P35968 1/20 0.38
RET P07949 1/20 0.38
DRD3 P35462 1/20 0.38
LMNA P02545 1/20 0.38
IKBKE Q14164 1/20 0.38
TBK1 Q9UHD2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6317590 0.89 SMN1; SMN2 (0.49) NPC1DEGS1RET
SCHEMBL6316805 0.89 CA1 (0.46) NPC1MEN1KMT2ARETLMNA
SCHEMBL6316770 0.89 LMNA (0.53) NPC1PTGS1MEN1KMT2ANPSR1
SCHEMBL6316752 0.88 IDO1 (0.42) NPC1MEN1KMT2A
SCHEMBL6323363 0.87 P2RY14 (0.47) NPC1MEN1KMT2AP2RY14RET
SCHEMBL6319264 0.86 NPC1 (0.47) NPC1STAT3STAT1PTGS1KDR
SCHEMBL6316187 0.86 KIT (0.46) NPC1MEN1KMT2AKDRRET
SCHEMBL6316808 0.84 SMN1; SMN2 (0.50) NPC1MEN1KMT2ANPSR1DEGS1
SCHEMBL6317604 0.84 DEGS1 (0.40) NPC1DEGS1RETIKBKETBK1
SCHEMBL6315543 0.83 TNIK (0.39) NPC1MEN1KMT2AKDRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 NPC1 3741/4885STAT3 300/4885STAT1 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.